Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SALMAN M FAZAL

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1588755904
CMS profile
298467
Location
PITTSBURGH, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$232,413.06

199 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SALMAN M FAZAL

NPI 1588755904 · CMS profile ID 298467

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

PITTSBURGH, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1588755904?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SALMAN M FAZAL, NPI 1588755904, CMS profile ID 298467. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588755904?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). SALMAN M FAZAL, NPI 1588755904, CMS profile ID 298467. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588755904?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
SALMAN M FAZAL, NPI 1588755904, CMS profile ID 298467, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1588755904?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

199 matching records · $232,413.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 199 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 199.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Taiho Oncology, Inc. $223.4909/10/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843383381 CMS
Taiho Oncology, Inc. $261.8109/10/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843383385 CMS
Taiho Oncology, Inc. $374.9809/10/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843383389 CMS
Taiho Oncology, Inc. $7,425.0009/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843383393 CMS
Taiho Oncology, Inc. $65.0009/10/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843383485 CMS
Celgene Corporation $4,310.0009/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853634185 CMS
Celgene Corporation $121.8209/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853634189 CMS
Janssen Biotech, Inc. $3,800.0008/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788432525 CMS
Taiho Oncology, Inc. $1,100.0008/27/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843383401 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,925.0008/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819923941 CMS
Incyte Corporation $3,690.0008/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835536421 CMS
Takeda Pharmaceuticals U.S.A., Inc. $107.1408/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819923939 CMS
Celgene Corporation $4,310.0008/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853634193 CMS
Celgene Corporation $13.8008/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853634197 CMS
Incyte Corporation $1,845.0008/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835536143 CMS
Incyte Corporation $2,460.0008/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835536151 CMS
Janssen Biotech, Inc. $93.6808/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788432517 CMS
Janssen Biotech, Inc. $629.5208/10/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788432521 CMS
Amgen Inc. $400.0008/06/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825758941 CMS
Karyopharm Therapeutics Inc. $4,063.0008/04/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845788603 CMS
Karyopharm Therapeutics Inc. $5.6608/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845788605 CMS
Celgene Corporation $96.2708/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853634201 CMS
Celgene Corporation $688.0008/03/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853634204 CMS
Celgene Corporation $626.2008/03/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853634207 CMS
Celgene Corporation $4,310.0008/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853634211 CMS
Celgene Corporation $259.3708/03/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853634215 CMS
GlaxoSmithKline, LLC. $4,200.0008/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802281727 CMS
Incyte Corporation $89.6008/01/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835536169 CMS
Incyte Corporation $4,920.0007/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835536425 CMS
Kite Pharma, Inc. $3,780.0007/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844413357 CMS
Kite Pharma, Inc. $84.3907/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844413361 CMS
GlaxoSmithKline, LLC. $122.0407/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801936213 CMS
Incyte Corporation $113.4007/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835536165 CMS
AbbVie Inc. $550.0007/01/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794446189 CMS
Janssen Biotech, Inc. $500.0007/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788432513 CMS
GlaxoSmithKline, LLC. $8.1906/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802800683 CMS
GENZYME CORPORATION $2,877.0006/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843601167 CMS
GENZYME CORPORATION $103.7506/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843601169 CMS
Incyte Corporation $112.1906/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835536147 CMS
Servier Pharmaceuticals LLC $1,410.0006/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852923215 CMS
Incyte Corporation $1,845.0006/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835536043 CMS
Incyte Corporation $6,150.0006/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835536061 CMS
Incyte Corporation $6,765.0006/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835536093 CMS
Incyte Corporation $20.6306/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835536051 CMS
Incyte Corporation $33.6006/01/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835536055 CMS
Incyte Corporation $38.0006/01/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835536057 CMS
Incyte Corporation $23.0006/01/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835536073 CMS
Incyte Corporation $10.8906/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835536075 CMS
Incyte Corporation $11.7706/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835536079 CMS
Incyte Corporation $8.2306/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835536089 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $253,501.49 231
PY2020 $190,061.25 149
PY2021 $232,413.06 199
PY2022 $303,219.79 263
PY2023 $367,406.14 302
PY2024 $398,925.66 392
PY2025 $579,790.31 418

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $65,614.85 12
PY2024 Principal investigator $45,518.53 10
PY2023 Principal investigator $62,558.13 14
PY2022 Principal investigator $94,680.26 17
PY2021 Principal investigator $96,789.15 23
PY2020 Principal investigator $40,338.98 30
PY2019 Principal investigator $187,337.60 58

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

12 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Sumitomo Pharma America, Inc. $4,646.85 12/31/2025 Non-covered Recipient Entity
WEST PENN HOSPITAL
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176658061
Principal investigator 1 Sumitomo Pharma America, Inc. $1,600.00 10/23/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176651451
Principal investigator 1 Sumitomo Pharma America, Inc. $331.50 07/24/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176641279
Principal investigator 1 Sumitomo Pharma America, Inc. $1,850.00 07/24/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176641283
Principal investigator 1 Sumitomo Pharma America, Inc. $15,100.00 07/24/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176641287
Principal investigator 1 Sumitomo Pharma America, Inc. $1,500.00 07/24/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176641291
Principal investigator 1 ABBVIE INC. $2,890.00 06/05/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1202490403
Principal investigator 1 Sumitomo Pharma America, Inc. $3,800.00 06/05/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176636126
Principal investigator 1 ABBVIE INC. $3,500.00 04/24/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1202478808
Principal investigator 1 Sumitomo Pharma America, Inc. $23,500.00 04/17/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP 5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation No dispute reported 06/30/2026 1176633512
Principal investigator 1 ABBVIE INC. $1,160.90 03/06/2025 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
M16-109 - A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1202458164
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,735.60 01/09/2025 Non-covered Recipient Entity
Allegheny-singer Research Institute (asri)
A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm- Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blo No dispute reported 06/30/2026 1235999145